Back to discover

Protein / target

Proteasome subunit alpha type-7

Encoded byPSMA7O14818Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Identical protein binding

Strongest disease association

Multiple Myeloma

Via encoding gene PSMA7 · Clinical evidence · score 0.60

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.

View complete UniProt function annotation

Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Inhibits the transactivation function of HIF-1A under both normoxic and hypoxia-mimicking conditions. The interaction with EMAP2 increases the proteasome-mediated HIF-1A degradation under the hypoxic conditions. Plays a role in hepatitis C virus internal ribosome entry site-mediated translation. Mediates nuclear translocation of the androgen receptor (AR) and thereby enhances androgen-mediated transactivation. Promotes MAVS degradation and thereby negatively regulates MAVS-mediated innate immune response

Subcellular location

CytoplasmNucleus
Domains and Gene Ontology detail (33)

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Cextracellular exosome
  • Cnucleoplasm
  • Cnucleus
  • Cproteasome complex
  • Cproteasome core complex
  • Cproteasome core complex, alpha-subunit complex
  • Cproteasome storage granule
  • Csynaptic vesicle
  • Fidentical protein binding
  • Papoptotic process

248 aa · 28 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell-cycle regulationGOImmune signallingUniProt · GO
View supporting evidence

Cell-cycle regulation

  • ·regulation of G1/S transition of mitotic cell cycle

Immune signalling

  • ·Component of the 20S core proteasome complex involved in the proteolytic degradation of…
  • ·CD8-positive, alpha-beta T cell differentiation
  • ·CD8-positive, alpha-beta T cell homeostasis
  • ·negative regulation of regulatory T cell differentiation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

3 medicines · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Multiple Myeloma1 medicine
Neoplasms3 medicines

5 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

4

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

bortezomib
ApprovedInhibitor

26S proteasome inhibitor

Indicated for Neoplasms

Acts on a complex — shared with PSMD1, PSMB2, PSMB1 +34 more · 1 of 38 recorded protein targets — broad pharmacology

carfilzomib
ApprovedInhibitor

26S proteasome inhibitor

Indicated for Multiple Myeloma, Neoplasms

Acts on a complex — shared with PSMD1, PSMB2, PSMB1 +34 more · 1 of 38 recorded protein targets — broad pharmacology

ixazomib
ApprovedInhibitor

26S proteasome inhibitor

Indicated for Neoplasms

Acts on a complex — shared with PSMD1, PSMB2, PSMB1 +34 more · 1 of 38 recorded protein targets — broad pharmacology

Oprozomib
Phase 2Inhibitor

26S proteasome inhibitor

Acts on a complex — shared with PSMD1, PSMB2, PSMB1 +34 more · 1 of 38 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PSMA7

Gene-level evidence surfaced through the gene PSMA7that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Multiple Myeloma
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Neoplasms
0.61Moderately supported

Clinical evidence dominant · Open Targets 0.49

Precursor Cell Lymphoblastic Leukemia-Lymphoma
0.45Limited support

Clinical evidence dominant · Open Targets 0.36

Lymphoma, Large B-Cell, Diffuse
0.41Limited support

Clinical evidence dominant · Open Targets 0.33

HIV Infections
0.30Preliminary

Pathway evidence dominant · Open Targets 0.46 · no direct causal or clinical evidence

View evidence synthesis (5)
Multiple MyelomaModerately supported
0.74
agreement 0.590.90
Clinical100%RNA expression1%

Open Targets aggregate 0.60 · 2 independent evidence families

NeoplasmsModerately supported
0.61
agreement 0.460.77
Clinical89%Literature12%

Open Targets aggregate 0.49 · 2 independent evidence families

Precursor Cell Lymphoblastic Leukemia-LymphomaLimited support
0.45
agreement 0.300.61
Clinical97%Literature3%

Open Targets aggregate 0.36 · 2 independent evidence families

Lymphoma, Large B-Cell, DiffuseLimited support
0.41
agreement 0.260.56
Clinical99%Literature1%

Open Targets aggregate 0.33 · 2 independent evidence families

HIV InfectionsPreliminary
0.30
agreement 0.130.48
Pathway99%Literature1%

Open Targets aggregate 0.46 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Multiple Myeloma0.60
Neoplasms0.49
HIV Infections0.46
Precursor Cell Lymphoblastic Leukemia-Lymphoma0.36
Lymphoma, Large B-Cell, Diffuse0.33

Drug development

7 compounds recorded · 5 approved · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 4 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (7)
IXAZOMIB CITRATEApproval
IXAZOMIBApproval
BORTEZOMIBApproval
CARFILZOMIBApproval
OPROZOMIBPhase 2
BORTEZOMIB D-MANNITOLApproval
MARIZOMIBPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-31

    A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

    Status changed to Active, not recruiting · ClinicalTrials.gov · via carfilzomib

  2. Trial status changed2026-07-30

    64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

    Status changed to Active, not recruiting · ClinicalTrials.gov · via bortezomib

  3. Regulatory approval2026-07-20

    Approval: CARFILZOMIB (ANDA209526)

    fda · regulatory · fda · via carfilzomib

  4. Withdrawn from market2025-08-07

    Market withdrawal: Bortezomib Hospira (EMA)

    ema · market · ema · via bortezomib

  5. Safety communication2019-11-21

    Drug Safety Update: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus

    mhra · safety · mhra · via carfilzomib

  6. Safety communication2019-08-19

    Drug Safety Update: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events

    mhra · safety · mhra · via carfilzomib

  7. Accelerated approval granted2015-11-19

    Accelerated approval: Kyprolis (EMA)

    ema · regulatory · ema · via carfilzomib

  8. Regulatory approval2015-07-20

    Approval: Bortezomib Accord (EMA)

    ema · regulatory · ema · via bortezomib

  9. New publication2011-08-01
    Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.

    Cancer investigation · 2011 · 12 citations · Europe PMC · via bortezomib

  10. New publication2011-02-21
    Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

    The Lancet. Oncology · 2011 · 66 citations · Europe PMC · via bortezomib

  11. New publication2010-12-14
    Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

    Cancer · 2011 · 31 citations · Europe PMC · via bortezomib

  12. New publication2010-02-08
    Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010 · 112 citations · Europe PMC · via bortezomib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.